Please select the option that best describes you:
Topics:
Lung Cancer • Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • Genomic Testing
Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?
Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.
Answer from: Medical Oncologist at Academic Institution
I think we always have to do our best to ensure we have adequate NGS. If tissue-based NGS on the initial biopsy is inadequate or negative, then a liquid biopsy is a good next step. However, if the liquid biopsy is negative for driver mutations, I would have a thorough discussion with the patient abo...
Sign in or Register to read more